



A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness: A Qualitative Analysis of Response Data

Victoria Di Virgilio¹, Amir Minerbi^{2,3}, Jenna Fletcher, Anthony Di Virgilio, Salena Aggerwal⁴, Luke Sheen⁵, Jagpaul Kaur Deol^{6,7}, Gaurav Gupta

Affiliations

¹ Carleton University, Ottawa

² Institute for Pain Medicine,

³ Faculty of Medicine, Technion Israel Institute of Technology

⁴ University of Ottawa

⁵ HaloHealth

⁶ University of British Columbia

⁷ Therapsil

Abstract

Background: The World Health Organization (WHO) defines wellness as the optimal state of health of individuals and groups. No study to date has identified the impact of psychedelic medicines for optimizing wellness using a dimensional approach. Treatment effects can be measured more broadly using a composite score of participants' global perceptions of change for pain, function, and mood scores. Given the precedence in previous work for retrospective study of participants' self-medicating with these substances, the nature of this study design allows for a safe way to develop further evidence in this area of care, with wellness as the broad indication.

Methods: 65 civilian or military veterans between the ages of 18-99 self-identifying as having used psychedelic medicines for non-recreational therapeutic purposes in the last 3 years were recruited for this study. Participants completed various standardized questionnaires that will be analyzed in a separate study, while this study analyzed the qualitative experiences described in relation to the medicines used and coded them according to themes developed from review of previous literature.

Results: A total of 93 comments were analyzed. Participant comments were classified into these categories: mysticism and spirituality, functional improvement and self awareness, social connection and cultural impact, impact on medical and mental health conditions, neutral impressions, sensations or difficult experiences. Participants described impacts in these categories related to spiritual, physiological, psychological, and social improvements, as well as difficulties and complex emotions regarding the experience of using psychedelic medicines.

Discussion: Wellness of individuals or groups is not simply an absence of disease, symptoms, or impairments. Rather, it reflects the outcome of numerous personal characteristics, psychophysiology, and choices, expressed throughout one's lifespan, unfolding in dynamic interaction with a complicated socio-cultural and physical environment. Participants that used psychedelic medicines described improvement of medical and mental health conditions, social interaction, spirituality, and overall function. In general, quality of life and wellness consequently improved after the use of these medicines based on established multidimensional factors.

Conclusion: The use of various psychedelic medicines appears to be associated with a broad range of qualitative experiences that could help clarify the mechanism of how they impact wellness in the future.

Keywords: Psychedelics, participant reported outcomes, Wellness, Dimensional measure, Retrospective, qualitative data

Background

The World Health Organization (WHO) constitution states: "Health is a state of complete physical, mental and social well-being and not



merely the absence of disease or infirmity." An important implication of this definition is that health is more than merely the absence of disorders or disabilities. Health is a state of well-being in which an individual realizes their own abilities, can cope with the normal stresses of life, can work productively and is able to contribute to their community. (*Health and Wellbeing*, n.d.).

A study examining the WHO's factors of quality of life (QOL), which include physical health, mental health, emotional well-being, and social functioning, concluded that the QOL concept is multidimensional (Baernholdt et al., 2012). The WHO considers wellness as the realization of the full potential of an individual physically, psychologically, socially, spiritually, and economically (*Health Promotion Glossary Update*, n.d.), thus quality of life and wellness are congruent in some areas, specifically mental and physical health, and social functioning.

Multiple dimensions underlying health and wellness cut across the diagnostic groups employed in classical categorical systems. These criteria-based categorical diagnostic systems are convenient for providers and service-providers, and are thus still frequently employed in medicine, public policy, and industry (e.g. insurance). However, the current movement toward personalized, precision-based, and participant-centered healthcare has empowered individuals to pursue professional care from a wide array of medical and allied health service providers. This is irrespective of whether a particular individual is deemed to meet the criteria for a particular diagnosis (Dawson, 1989; Kraft & Goodell, 1993).

Consider for example that there is a significant comorbidity between mental health and chronic pain issues (Cucinello-Ragland & Edwards, 2021; Kleykamp et al., 2021; Kohrt et al., 2018),

yet it is rare that participants afflicted with both are included in studies, therefore outcomes on a given treatment for either/both are challenging to differentiate (Kirsh, 2010; McParland et al., 2021; Myhr & Augestad, 2013; Weeks et al., 2016). Some authors argue a causative relationship, while others point to the overlap in symptomatology, functional issues, and treatments making diagnostic distinctions difficult (Aronoff, 2016; Fornasari, 2012; Kynast et al., 2013; Rieder et al., 2017).

Furthermore definitions employed by the Diagnostic and Statistical Manuals (DSM) show the interrater reliability is poor, diagnostic criteria lack specificity and treatment outcomes are not necessarily tied to clinical parameters (Bremmer et al., 2008; Hahn et al., 2010; Lacasse & Leo, 2005; Liebllich et al., 2015; Liu et al., 2015; Maas et al., 2009; Osimo et al., 2020). In addition, prescriptions for antidepressant medications have far outnumbered the amount of individuals diagnosed with depression, objective data supporting the DSMs diagnostic criteria for conditions is limited, and there have been concerns about industry influence on these guidelines in the past (Moncrieff, 2018; Whitaker, 2005). That is why numerous authors have advocated for a dimensional approach to evaluation which is based on symptomatology, severity, life impact and response to treatment, instead of diagnostic categories (Brown & Barlow, 2005; Coghill & Sonuga-Barke, 2012; Widiger & Samuel, 2005). This would allow for individuals with various degrees of symptomatology to be compared irrespective of their underlying clinical diagnosis.

There are numerous limitations to the existing treatments employed as standard of care for specific categorically defined conditions (Benish et al., 2008; Cloitre, 2009; Foa et al., 2009; Hembree et al., 2003; Karlin et al., 2010;



Nemeroff et al., 2006; Rothbaum et al., 2006; *Treatment of Posttraumatic Stress Disorder*, 2008; Ursano et al., 2004). Moreover, various other studies have investigated aspects of wellness including risk factors, anthropomorphology, physical and emotional symptomatology, occupational impact, quality of life, societal participation and daily function (i.e. activities of daily living). Interventions aimed at improving wellness have included behavioral modifications, education, exercise programs, workplace modifications and preventative screening programs (Martínez-Lemos, 2015).

Emerging studies on the use of psychedelics for various indications have shown some early optimism in various categorical conditions, ranging from addiction, mood, pain and anxiety disorders, and end of life of care (Bornemann et al., 2021; Gasser et al., 2015; Malone et al., 2018; Nielson et al., 2018; Watts et al., 2017). Specifically, only categorical/diagnostic conditions like depression or pain have been used to select participants and categorize outcomes. This limits the ability to use the data in a real world setting where participants suffer from more than one health issue or do not meet any specific criteria for a condition. Also given that various psychedelic medicines function and are employed in a similar way, and are likely safe long term, it would be useful to comparatively study them for people self-medicating with psychedelics for their own wellness. This approach will hopefully help develop a better understanding of where these medicines provide relief and at what magnitude (Bornemann et al., 2021; Castellanos et al., 2020; Tupper et al., 2015).

Psychedelic drugs have varying pharmacological profiles that have strong effects on the conscious experience, and can be discussed in two classes. Classic psychedelics include lysergic acid diethylamide [LSD], psilocybin,

dimethyltryptamine [DMT] and mescaline exert their effect through the serotonin system particularly the 5HT_{2A} receptor. The other category are entactogens such as 3,4-methylenedioxy-methamphetamine (MDMA), which are primarily phenethylamines and amphetamines (Tupper et al., 2015). Emerging studies on the use of psychedelics for various indications have shown some early optimism in various categorical conditions, ranging from addiction, mood, pain and anxiety disorders, and end of life of care (Krebs & Johansen, 2013; Mayor, 2019; Schlag et al., 2021). Clinical evidence to date in the use of psychedelics for chronic pain is limited; however, several studies and reports over the past 50 years have shown potential analgesic benefit in cancer pain, phantom limb pain and cluster headaches (Castellanos et al., 2020).

There are numerous limitations of existing studies, with more data required to determine applications to clinical practice (Else, 2017; Herzog et al., 2018; Pratt et al., 2019; Tupper et al., 2015). However, possible clinical benefits include; reduced severity of anxiety/mood and possibly pain symptoms, longer term clinical effect without maintenance therapy, less reliance on plant-based cannabis and possible reduced rates of substance abuse and relapse, bolstered prosocial behavior, reduced public healthcare utilization and improved reintegration from a personal, community, occupational (Else, 2017; Herzog et al., 2018; Nielson et al., 2018; Schlag et al., 2021; Tupper et al., 2015).

Despite the early optimism much needs to be understood about the indications, contraindications, dosing, relative efficacy compared to other similar treatments, impact on dimensional aspects of wellness in “non pathologic” states, and cost benefit. No study to date has looked at the impact of psychedelics for treatment of wellness as specifically only



categorical/diagnostic criteria have been used to select participants and categorize outcomes. This further limits the ability to extrapolate outcomes to a real world setting (Brown & Barlow, 2005; Widiger & Samuel, 2005).

Given the overlap in mechanism of action of the various psychedelics, the known long term safety profile and the similarity in proposed clinical protocols for use, a dimensional approach will yield a more robust understanding of where these medicines help and by how much. Treatment effects can therefore be measured more broadly using a composite score of participant global perception, along with pain, function and mood scores, which has not been done to date.

Quantitative outcomes are generally more efficient to look at, but may not fully reflect the complexity of an experience. Previous qualitative studies regarding the use of psychedelic therapy have used various coding strategies to develop themes and categories based on therapy session transcripts. These techniques include thematic analysis (Clarke & Braun, 2017; Watts et al., 2017), computer assisted qualitative data analysis software (Belser et al., 2017), and qualitative content analysis (Gasser et al., 2015). These studies found that LSD-assisted psychotherapy in participants with severe mental illness associated with a life threatening disease provided secure and stable treatment results along with no serious negative effects (Gasser et al., 2015). In addition, psilocybin-assisted psychotherapy may provide psychologically distressed cancer participants with an efficacious treatment for mental and emotional distress (Belser et al., 2017). The effects may be divergent to antidepressants and short term talk therapies (Watts et al., 2017). The methods for analyzing qualitative data must reflect a broad range of experiences from participants, thus a

compilation of these methods allows for an in depth analysis.

The overall aim of this specific study is to retrospectively assess the participants' qualitative experience of using psychedelic medicines for improving their own wellness. Quantitative results related to the impact on wellness will be presented elsewhere.

Methods

Given the previous precedence for retrospective study of participants self-medicating with psychedelics, the nature of this study design allows for a safe way to develop further evidence in this area of care (Bornemann et al., 2021; Schindler et al., 2015). The clinical trial registration number is NCT05469243.

65 participants self-identifying as having used psychedelic medicine for non-recreational purposes were recruited for this study. To be considered eligible for admission to the study they were civilian or military veterans between the ages of 18-99 with a self-reported past of psychedelic medicine used for therapeutic purposes in the last 3 years. Past psychedelic medicine use for only non-therapeutic purposes (as determined by the participant) was excluded, as well as active military members.

In addition to demographic information, participants completed the following psychometric measures: Patient Global Impression of Change (PGIC) scale measured for overall quality of life, anxiety, mood, pain and disability subscales, the Pain, Enjoyment of Life and General Activity (PEG) scale, the Hospital Anxiety and Depression (HAD) scale, and the Disability Index (DI). Participants also provided information on their past medical history, nature/indications for use (ie. depression, PTSD, chronic pain, other), and adverse events. The scores are expressed on the



basis of how they felt at the time of reporting in relation to the numerous dimensions of wellness. No change in scores were measured. A deeper quantitative analysis will be provided in a separate study.

This specific article will examine the qualitative responses of the data collected in the comments. Comments were classified into categories using a modification of the previously described qualitative paper coding techniques (Belser et al., 2017; Gasser et al., 2015; Watts et al., 2017) and thematic analysis (Clarke & Braun, 2017). The comments were then analyzed by integrating categories from other previous qualitative studies (Belser et al., 2017; Gasser et al., 2015; Watts et al., 2017). Thematic analysis included the categories developed for this paper based on previous work, in order to identify the main themes presented in the comments (Watts et al., 2017).

Two authors (VD, GG) organized and reviewed the comments using the primary medicine and themes derived, which are presented in Appendix A. The primary categories applied were A) Mysticism/spirituality; B) Functional improvement/self awareness; C) Social connection/cultural impact; D) Impact on medical/mental health condition; and E) Neutral impression, sensations or difficult experiences. Comments were also further sub-categorized using the same themes if required.

Results

Of the 65 questionnaires completed 38 were by women, with an average age of 45.1 years old. Twenty of the 38 women were unemployed or on a leave of absence compared to only 5 men, while the most cited medical conditions were anxiety and depression. Psilocybin and Ayahuasca were the most common medicines used, while 11 participants did not report which

psychedelic they had used most recently. Average scores for the participant reported outcomes fell into the mild- moderate range depending on the measure. Table 1 & 2 further describes the demographics and outcomes of the various participant reported outcomes.



Table1: Demographics of Participants

	Men (n=24)	Women (n=38)	Other (n=2)
<i>Age</i>			
Average	45.4	45.1	59
<i>Work</i>			
Full-time	17	13	1
Part-time	2	5	1
Unemployed and/or current leave of absence	5	20	0
<i>Diagnoses Reported</i>			
Addiction	7	7	0
Anxiety	10	27	0
Chronic pain	8	18	1
Depression	15	25	1
End of life distress	0	2	0
PTSD	8	19	1
<i>Most Recent Medication Used</i>			
Ayahuasca	2	6	0
Ecstasy	0	3	0
Ibogaine	1	1	0
Ketamine	1	4	0
Lysergic Acid Diethylamide	1	2	0
Cannabis	2	1	0
Methamphetamine	0	2	0
Psilocybin	12	13	2
None	5	6	0



Table 2: Pain, Enjoyment and General Activity Scale (PEG), Disability Index (DI), and Hospital Anxiety and Depression (HAD) scores, including HAD depression and anxiety subscales.

	Men (n=24)	Women (n=38)	Other (n=2)
<i>Current PEG score</i>			
Average	11.5	14.0	18.5
<i>Current DI score</i>			
Average	23.8	32.0	37.5
<i>Current HAD score</i>			
Average	15.2	17.9	20
<i>Current HAD depression subscale</i>			
Average	6.4	7.1	8.5
<i>Current HAD anxiety subscale</i>			
Average	8.8	10.8	11.5

Note: PEG (Pain, Enjoyment and General Activity Scale), DI (Disability Index), HAD (Hospital Anxiety and Depression Scale)



Table 3: Medications taken resulting in comments from participants describing the impact and experience of psychedelic therapy for wellness associated with specific categories.

Medication	Category					Total comments for medication
	A Mysticism/ spirituality	B Functional improvement/ self Awareness	C Social connection/ Cultural Impact	D Impact on medical/ mental health condition	E Neutral impression, sensations or difficult experiences	
<i>Ayahuasca</i>	3	7	2	5	0	17
<i>Ecstasy</i>	0	1	1	0	1	3
<i>Ibogaine</i>	0	0	0	1	0	1
<i>Ketamine</i>	2	1	0	1	3	7
<i>Lysergic Acid Diethylamide</i>	2	0	0	2	1	5
<i>Cannabis</i>	0	1	0	0	2	3
<i>Methampheta mine</i>	1	0	0	1	3	5
<i>Psilocybin</i>	15	14	2	15	5	51
<i>None</i>	0	0	0	0	1	1
<i>Total comments for Category</i>	23	24	5	25	16	93

Table 3 describes the reported experience and impact of psychedelic therapy on wellness organized into 5 principal categories by medication. There were 17 comments for ayahuasca, 3 for ecstasy, 1 for ibogaine, 7 for ketamine, 5 for lysergic acid diethylamide, 3 for marijuana, 5 for methamphetamine, 51 for psilocybin, and 1 for no associated medication. Comments associated with the medications psilocybin and ayahuasca were the most abundant, together making up 73.1% of all comments. Themes related to categories A, B and E were the most commonly reported, representing over 75% of all comments combined.



Table 4: Qualitative analysis of comment occurrences in categories, including subcategory occurrences

Categories	Occurrences			
	Category	Subcategory	Total	%
A Mysticism/ spirituality	23	13	36	38.7
B Functional improvement/ self Awareness	24	11	35	37.6
C Social connection/ Cultural Impact	5	9	14	15.1
D Impact on medical/ mental health condition	25	10	35	37.6
E Neutral impression, sensations or difficult experiences	16	23	39	41.9

93 comments total, Appendix A.

Numerous comments had multiple thematic elements. Table 4 shows the number of comments categorised and sub categorised into each theme. Three of the comments left by participants were originally in French, but were translated into English for the purposes of comprehension and consistency. No other changes were made to the comments. These are displayed in full in Appendix A.

Mysticism and Spirituality

Some participants described experiences and lasting effects of a religious or spiritual essence. They expressed that psychedelic therapy provided support for reconnection or revelational moments related to their connection with various religions, mind and body, soul, and life's purpose. Comments ranged from mystical and spiritual experiences to ego dissolution, detachment, confusion. Subcategories from previous qualitative studies that were integrated into this classification included connection to a spiritual principle, and/or oneself (Watts et al., 2017). Spiritual and religious experiences were

found in 36 comments, including comments from the subcategories.

“shaking; nausea; yawning; visual effects (intensely detailed, exquisite and ethereal patterns and visions; connection with and guidance from holy spirit; revelatory messages of life's purpose and meaning; unforgettable experiences of infinite, eternal, divine love”

This participant revealed how they felt connected to religion and spirituality. Their experience with psychedelic therapy offered insights to life's meaning and allowed them to perceive lasting feelings of love.

Functional Improvement and Self Awareness

Many of the participants expressed valuable improvement of their daily activities as well as newfound self-awareness leading to more positive daily experiences. Functional improvement has to do with the



improvement of daily activities. Some of the comments discussed release of emotional loads, positive changes to activities and habits, and elements of self awareness. Subcategories that were integrated into this classification based on previous qualitative studies are revised life priorities (Belser et al., 2017), increased quality of life, faster progress, physical well-being, increased awareness, and important introspection (Gasser et al., 2015). Functional improvement and self awareness was found to have been improved in 35 comments, including comments classified in subcategories.

“I have a clearer understanding of where my mental health and any physical pain play a role in my life; I have a better acceptance of things in my life and am not held back by these things.”

This participant developed stronger self awareness which allowed them to improve their daily functioning.

Social Connection and Cultural Impact

Social connection necessary for interpersonal relationships was found to be improved in a number of participants as well as specific cultural experiences provided by the psychedelic medicine. A participant who saw cultural impacts described how the medicine changed their perspective on indigenous worldviews. Other participants described various elements in which their interpersonal relationships became improved after integrating the experience with the psychedelic medicine into their lives, but some participants traversed through difficult experiences in order to reach the improvement in their relationships. Themes from previous qualitative studies that were integrated into this classification are improved relationships after treatment, from separateness to interconnectedness (Belser et al., 2017),

increased importance of family (Gasser et al., 2015), connection to the world, and connection to others (Watts et al., 2017). Social connection and cultural elements were improved in 14 comments, including comments classified in subcategories.

“purging, shaking, crying, spiritual experiences (feeling of being loved, feeling of connection to humanity), intense emotional processing (processing of past attachment injuries, meaning making, self-compassion, moving through unfinished business in interpersonal relationships [parents, past romantic attachments])”

Interpersonal relationships with parents and past romantic companions were topics of distress for this participant, but the psychedelic therapy for wellness allowed them to transcend those difficulties and improve future interpersonal relationships.

Impact on medical and mental health condition

Participants experienced a variety of changes to their conditions resulting in an improved quality of life and improved wellness. This classification could resonate with many participants as they all have some sort of medical or mental health condition that may cause certain limitations of function, pain, and psychological distress. There were many accounts of reduced pain (general, localized and chronic pain), reduced anxiety and/or reduced symptoms associated with specific mental health conditions. Some participants described that the reduction in symptoms did not last long, and difficulties with accessing psychedelics. The subcategories from previous qualitative studies that were integrated into this classification along with general reduction in psychological and physiological conditions are reduced anxiety and increased mental strength (Gasser et al., 2015).



Impact on both medical and mental health conditions were improved in 35 comments, including comments classified in subcategories.

“Mental resolution, removed brain fog, relieved pain in my joints and head, relieved anxiety for up to about a month”

One participant expressed the impact of psychedelic therapy on various aspects of their mental and physical health. They experienced reduced symptoms associated with their anxiety and physical pain. Although the participant did factor in how the relief only lasted for a certain period of time after taking the psychedelic.

Neutral impression, sensations or difficult experiences

Some participants experienced different impacts regarding the impact of psychedelic therapy for wellness that do not fall into a category that represents a form of mental, physical, or functional improvement. Participants left comments regarding side effects, setbacks due to lack of medication access, and various sensations including purging, nausea, vomiting, and shaking. Themes from previous qualitative studies that were integrated into this category include surrender or “letting go” following transient psychological distress, continued struggle, catharsis of powerful emotion (Belser et al., 2017), disconnection, and the confrontation of traumatic memories from childhood (Watts et al., 2017). This section represents participants that generally experienced physiological sensations, or difficult experiences, although some comments are classified in other subcategories. These themes were found in 39 comments, including comments classified in subcategories.

“the only associated symptom that I got after a "Trip" was fatigue, some expected anxiety prior too”

As described in the participant comment, they experienced some effects such as anxiety and fatigue.

Discussion

Wellness of individuals or groups is not simply an absence of disease, symptoms, or impairments. It is rather the outcome of numerous personal characteristics, psychophysiology, and choices, expressed throughout one's lifespan, unfolding in dynamic interaction with a complicated socio-cultural and physical environment. The accumulation of research in fields such as physiology, medicine, and neuroscience has highlighted that comorbidity is the norm, and thus there is limited external validity or clinical utility to studies that isolate small samples of individuals with "pure" diagnoses by excluding the majority of persons (Endresen & Wintz, 1988; Grasser & Craft, 1984; Magnavita & Garbarino, 2017; C. K. Ross et al., 1987).

Despite the ubiquitous nature of suffering and vast array of choices, the relative and/or synergistic benefit of commonly employed treatments for wellness such as rehabilitation, mental health support, medications, injections and surgery have never been convincingly elucidated (Frass et al., 2012; Giannitrapani et al., 2019; Herman et al., 2005; van der Watt et al., 2008). Studies are limited by heterogeneity of conditions, lack of standardization of measurement, small sample sizes, lack of statistical power, small effect sizes and questionable durability of responses, (P. T. Ross & Bibler Zaidi, 2019; Zwahlen et al., 2008). This limits our ability to draw generalizable conclusions resulting in (a) a limited understanding of real world/societal implications



of treatments; (b) a limited ability to extrapolate to varied populations/edge cases; (c) poor control for placebo effects; (d) a limited understanding of synergies between different types of care; as well as (e) a need to evolve care pathways and test the validity of current diagnostic criteria/consensus statements regarding care (Frass et al., 2012; Herman et al., 2005; P. T. Ross & Bibler Zaidi, 2019; Zwahlen et al., 2008). However these treatments are routinely used, often at great cost and unknown risk, in caring for people in many use cases such as non-pathologic suffering/life concerns, primary/secondary mental health conditions, chronic pain and end of life concerns (van der Watt et al., 2008).

Health systems and employers are increasingly looking to wellness programs as a cost-containment strategy, given the disproportionate share of medical expenditures, and absenteeism with noncommunicable diseases. One systematic review that looked at interventions targeting one of the four primary modifiable behaviors for chronic disease: physical activity, healthy diet, tobacco use, and harmful consumption of alcohol, did not show wellness programs deliver a positive return on investment within the first few years of initiation (Baid et al., 2021). Conversely, despite the high degree of heterogeneity between the studies, limited effect size and risk bias potential in other studies, some research has shown improvements in wellness for participants with multiple sclerosis, employees reporting stress, and health professionals at risk of burnout (Morrison & MacKinnon, 2008; O'Reilly et al., 2018; Richardson, 2017; Russell et al., 2020; Slavin et al., 2014; Weiss et al., 2021).

With respect to the participants in this study, many described improvements in multiple domains of wellness associated with psychedelic medicines. Similar to other studies, this included

effects on medical and mental health conditions, social interaction, spirituality, and functional improvement, and quality of life, all established multidimensional factors related to wellness (Baernholdt et al., 2012). While there were negative consequences reported as well, in general there were one or more life domains positively impacted from a qualitative standpoint. The factors driving these effects will require further exploration in order to explain the mechanism of change for dimensional measures of wellness.

While Psilocybin and Ayahuasca were most commonly reported in this study, the thematic qualitative experiences were not unique to any single medicine, nor did a single theme always emerge for any given participant. This is consistent with existing literature, although the thematic changes at a granular level and effect size for each medicine and related experiences will likely require more study (Gasser et al., 2015; Watts et al., 2017). The long term goal of this type of research would be to determine if the perceived benefits are class or medicine specific, and what factors about the participant selection and treatment can conceivably be changed to facilitate outcomes (Belser et al., 2017). If this can further be tied to the neurobiology of the medicine and patient, a set of truly bespoke treatment options can emerge (Nielson et al., 2018).

The language used to express the experience may also be context, medicine and patient dependent. Examining how the words used to describe and reflect on the experience are influenced by various factors like preparation, expectation, health issues, culture and intention will be important. Defining a common language or validated set of themes with which to draw from might help facilitate understanding of these medicines and help extrapolate their applications more broadly (Malone et al., 2018). The effect



of this understanding will help further clarify the combined qualitative and quantitative effects of these medications.

Limitations of this study include the retrospective nature and sample size. The results were based on self report, while time since administration and change in patient reported outcomes were not collected or standardized. Also unlike other studies, the qualitative information was not gathered through in person interviews, and commenting was left to the discretion of individual participants. Future studies can look further at a more structured thematic assessment to validate the categories developed here and to see what other themes may emerge. Finally while the impact of each medication for various domains needs to be elucidated more fully, understanding the neurophysiological effect will be key in treatment planning and personalization of care.

Conclusion

The use of various psychedelic medicines appears to be associated with a broad range of qualitative experiences that could help clarify the mechanism of how they impact wellness in the future. Broadly speaking various circumscribed themes emerge when individual experiences are described, spanning multiple domains. While this qualitative impact could be class or medicine specific, eventually with a validated set of language tools and an improved understanding of the neurobiology, qualitative and quantitative outcomes may become more predictable. This would be imperative in designing patient specific treatments using these medicines in the future.



References

- Aronoff, G. M. (2016). What Do We Know About the Pathophysiology of Chronic Pain? Implications for Treatment Considerations. *The Medical Clinics of North America*, 100(1), 31–42. <https://doi.org/10.1016/j.mcna.2015.08.004>
- Baernholdt, M., Hinton, I., Yan, G., Rose, K., & Mattos, M. (2012). Factors associated with quality of life in older adults in the United States. *Quality of Life Research*, 21(3), 527–534. <https://doi.org/10.1007/s11136-011-9954-z>
- Baid, D., Hayles, E., & Finkelstein, E. A. (2021). Return on Investment of Workplace Wellness Programs for Chronic Disease Prevention: A Systematic Review. *American Journal of Preventive Medicine*, 61(2), 256–266. <https://doi.org/10.1016/j.amepre.2021.02.002>
- Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S., Devenot, N., Friedman, H. L., Guss, J., Bossis, A., & Ross, S. (2017). Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis. *Journal of Humanistic Psychology*, 57(4), 354–388. <https://doi.org/10.1177/0022167817706884>
- Benish, S. G., Imel, Z. E., & Wampold, B. E. (2008). The relative efficacy of bona fide psychotherapies for treating post-traumatic stress disorder: A meta-analysis of direct comparisons. *Clinical Psychology Review*, 28(5), 746–758. <https://doi.org/10.1016/j.cpr.2007.10.005>
- Bornemann, J., Close, J. B., Spriggs, M. J., Carhart-Harris, R., & Roseman, L. (2021). Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research. *Frontiers in Psychiatry*, 12, 735427. <https://doi.org/10.3389/fpsy.2021.735427>
- Bremner, M. A., Beekman, A. T. F., Deeg, D. J. H., Penninx, B. W. J. H., Dik, M. G., Hack, C. E., & Hoogendijk, W. J. G. (2008). Inflammatory markers in late-life depression: Results from a population-based study. *Journal of Affective Disorders*, 106(3), 249–255. <https://doi.org/10.1016/j.jad.2007.07.002>
- Brown, T. A., & Barlow, D. H. (2005). Dimensional versus categorical classification of mental disorders in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders and beyond: Comment on the special section. *Journal of Abnormal*



<i>Psychology</i> , 114(4), 551–556.	511.x
https://doi.org/10.1037/0021-843X.114.4.55	Cucinello-Ragland, J. A., & Edwards, S. (2021).
1	Neurobiological aspects of pain in the
Castellanos, J. P., Woolley, C., Bruno, K. A., Zeidan,	context of alcohol use disorder.
F., Halberstadt, A., & Furnish, T. (2020).	<i>International Review of Neurobiology</i> , 157,
Chronic pain and psychedelics: A review	1–29.
and proposed mechanism of action.	https://doi.org/10.1016/bs.irn.2020.09.001
<i>Regional Anesthesia & Pain Medicine</i> ,	Dawson, S. (1989). Health care consumption and
45(7), 486–494.	consumer social class: A different look at
https://doi.org/10.1136/rapm-2020-101273	the patient. <i>Journal of Health Care</i>
Clarke, V., & Braun, V. (2017). Thematic analysis.	<i>Marketing</i> , 9(3), 15–25.
<i>The Journal of Positive Psychology</i> , 12(3),	Elsey, J. W. B. (2017). Psychedelic drug use in
297–298.	healthy individuals: A review of benefits,
https://doi.org/10.1080/17439760.2016.1262	costs, and implications for drug policy. <i>Drug</i>
613	<i>Science, Policy and Law</i> , 3,
Cloitre, M. (2009). Effective psychotherapies for	205032451772323.
posttraumatic stress disorder: A review and	https://doi.org/10.1177/2050324517723232
critique. <i>CNS Spectrums</i> , 14(1 Suppl 1),	Endresen, K. W., & Wintz, J. C. (1988). HealthStyles:
32–43.	A new psychographic segmentation system
Coghill, D., & Sonuga-Barke, E. J. S. (2012). Annual	for health care marketers. <i>The Journal of</i>
research review: Categories versus	<i>Medical Practice Management: MPM</i> , 3(4),
dimensions in the classification and	273–277.
conceptualisation of child and adolescent	Foa, E. B., Keane, T. M., Friedman, M. J., & Cohen,
mental disorders--implications of recent	J. A. (2009). Effective treatments for PTSD:
empirical study. <i>Journal of Child</i>	Practice guidelines from the International
<i>Psychology and Psychiatry, and Allied</i>	Society for Traumatic Stress Studies, 2nd
<i>Disciplines</i> , 53(5), 469–489.	ed. <i>International Society Traumatic Stress</i>
https://doi.org/10.1111/j.1469-7610.2011.02	<i>Studies</i> , 2.



- 00
 - 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
 - 61
 - 62
 - 63
 - 64
 - 65
 - 66
 - 67
 - 68
 - 69
 - 70
 - 71
 - 72
 - 73
 - 74
 - 75
 - 76
 - 77
 - 78
 - 79
 - 80
 - 81
 - 82
 - 83
 - 84
 - 85
 - 86
 - 87
 - 88
 - 89
 - 90
 - 91
 - 92
 - 93
 - 94
 - 95
 - 96
 - 97
 - 98
 - 99
- <https://psycnet.apa.org/record/2008-18599-0>
- Fornasari, D. (2012). Pain mechanisms in patients with chronic pain. *Clinical Drug Investigation, 32 Suppl 1*, 45–52.
- <https://doi.org/10.2165/11630070-000000000-0-00000>
- Frass, M., Strassl, R. P., Friehs, H., Müllner, M., Kundi, M., & Kaye, A. D. (2012). Use and acceptance of complementary and alternative medicine among the general population and medical personnel: A systematic review. *The Ochsner Journal, 12*(1), 45–56.
- Gasser, P., Kirchner, K., & Passie, T. (2015). LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. *Journal of Psychopharmacology, 29*(1), 57–68.
- <https://doi.org/10.1177/0269881114555249>
- Giannitrapani, K. F., Holliday, J. R., Miake-Lye, I. M., Hempel, S., & Taylor, S. L. (2019). Synthesizing the Strength of the Evidence of Complementary and Integrative Health Therapies for Pain. *Pain Medicine (Malden, Mass.), 20*(9), 1831–1840.
- <https://doi.org/10.1093/pm/pnz068>
- Grasser, C., & Craft, B. J. (1984). The patient’s approach to wellness. *The Nursing Clinics of North America, 19*(2), 207–218.
- Hahn, T., Marquand, A. F., Ehli, A.-C., Dresler, T., Kittel-Schneider, S., Jarczok, T. A., Lesch, K.-P., Jakob, P. M., Mourao-Miranda, J., Brammer, M. J., & Fallgatter, A. J. (2010). Integrating Neurobiological Markers of Depression. *Archives of General Psychiatry, 68*(4), 361.
- <https://doi.org/10.1001/archgenpsychiatry.2010.178>
- Health and Wellbeing. (n.d.). World Health Organization. Retrieved March 5, 2022, from <https://www.who.int/data/gho/data/major-themes/health-and-well-being>
- Health Promotion Glossary Update. (n.d.). World Health Organization. Retrieved March 5, 2022, from https://www.who.int/healthpromotion/about/HPR%20Glossary_New%20Terms.pdf
- Hembree, E. A., Foa, E. B., Dorfan, N. M., Street, G. P., Kowalski, J., & Tu, X. (2003). Do patients drop out prematurely from exposure therapy for PTSD? *Journal of Traumatic Stress, 16*(6), 555–562.
- <https://doi.org/10.1023/B:JOTS.0000004078>



-
- .93012.7d 39–47.
- Herman, P. M., Craig, B. M., & Caspi, O. (2005). Is complementary and alternative medicine (CAM) cost-effective? A systematic review. *BMC Complementary and Alternative Medicine*, 5(1), 11. <https://doi.org/10.1186/1472-6882-5-11>
- Herzog, S., Shanahan, M., Grimison, P., Tran, A., Wong, N., Lintzeris, N., Simes, J., Stockler, M., & Morton, R. L. (2018). Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. *Pharmacoeconomics*, 36(1), 67–78. <https://doi.org/10.1007/s40273-017-0565-6>
- Karlin, B. E., Ruzek, J. I., Chard, K. M., Eftekhari, A., Monson, C. M., Hembree, E. A., Resick, P. A., & Foa, E. B. (2010). Dissemination of evidence-based psychological treatments for posttraumatic stress disorder in the Veterans Health Administration. *Journal of Traumatic Stress*, 23(6), 663–673. <https://doi.org/10.1002/jts.20588>
- Kirsh, K. L. (2010). Differentiating and Managing Common Psychiatric Comorbidities Seen in Chronic Pain Patients. *Journal of Pain & Palliative Care Pharmacotherapy*, 24(1), 39–47. <https://doi.org/10.3109/15360280903583123>
- Kleykamp, B. A., Ferguson, M. C., McNicol, E., Bixho, I., Arnold, L. M., Edwards, R. R., Fillingim, R., Grol-Prokopczyk, H., Turk, D. C., & Dworkin, R. H. (2021). The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: An ACTION systematic review. *Seminars in Arthritis and Rheumatism*, 51(1), 166–174. <https://doi.org/10.1016/j.semarthrit.2020.10.006>
- Kohrt, B. A., Griffith, J. L., & Patel, V. (2018). Chronic pain and mental health: Integrated solutions for global problems. *Pain*, 159(1), S85–S90. <https://doi.org/10.1097/j.pain.0000000000001296>
- Kraft, F. B., & Goodell, P. W. (1993). Identifying the health conscious consumer. *Journal of Health Care Marketing*, 13(3), 18–25.
- Krebs, T. S., & Johansen, P.-Ø. (2013). Psychedelics and mental health: A population study. *PLoS One*, 8(8), e63972. <https://doi.org/10.1371/journal.pone.0063972>
- Kynast, K. L., Russe, O. Q., Geisslinger, G., & Niederberger, E. (2013). Novel findings in



- 2 pain processing pathways: Implications for
miRNAs as future therapeutic targets. *Expert Review of Neurotherapeutics*, 13(5), 515–525. <https://doi.org/10.1586/ern.13.34>
- Lacasse, J. R., & Leo, J. (2005). Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature. *PLoS Medicine*, 2(12), e392. <https://doi.org/10.1371/journal.pmed.0020392>
- Lieblich, S. M., Castle, D. J., Pantelis, C., Hopwood, M., Young, A. H., & Everall, I. P. (2015). High heterogeneity and low reliability in the diagnosis of major depression will impair the development of new drugs. *BJPsych Open*, 1(2), e5–e7. <https://doi.org/10.1192/bjpo.bp.115.000786>
- Liu, T., Zhong, S., Liao, X., Chen, J., He, T., Lai, S., & Jia, Y. (2015). A Meta-Analysis of Oxidative Stress Markers in Depression. *PloS One*, 10(10), e0138904. <https://doi.org/10.1371/journal.pone.0138904>
- 4 Maas, D. W., van der Mast, R. C., & de Craen, A. J. M. (2009). Increased C-reactive protein is not associated with apathy: The Leiden 85-Plus Study. *International Journal of Geriatric Psychiatry*, 24(11), 1177–1184.
- <https://doi.org/10.1002/gps.2242>
- Magnavita, N., & Garbarino, S. (2017). Sleep, Health and Wellness at Work: A Scoping Review. *International Journal of Environmental Research and Public Health*, 14(11), 1347. <https://doi.org/10.3390/ijerph14111347>
- Malone, T. C., Mennenga, S. E., Guss, J., Podrebarac, S. K., Owens, L. T., Bossis, A. P., Belser, A. B., Agin-Liebes, G., Bogenschutz, M. P., & Ross, S. (2018). Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. *Frontiers in Pharmacology*, 9, 256. <https://doi.org/10.3389/fphar.2018.00256>
- Martínez-Lemos, R. I. (2015). Economic impact of corporate wellness programs in Europe: A literature review. *Journal of Occupational Health*, 57(3), 201–211. <https://doi.org/10.1539/joh.14-0217-RA>
- Mayor, S. (2019). WHO proposes rescheduling cannabis to allow medical applications. *BMJ (Clinical Research Ed.)*, 364, 1574. <https://doi.org/10.1136/bmj.1574>
- McParland, J. L., Andrews, P., Kidd, L., Williams, L., & Flowers, P. (2021). A scoping review to ascertain the parameters for an evidence synthesis of psychological interventions to improve work and wellbeing outcomes



- hr/>
- among employees with chronic pain. *Health Psychology and Behavioral Medicine*, 9(1), 25–47. <https://doi.org/10.1080/21642850.2020.1863809>
- Moncrieff, J. (2018). Against the stream: Antidepressants are not antidepressants – an alternative approach to drug action and implications for the use of antidepressants. *BJPsych Bulletin*, 42(1), 42–44. <https://doi.org/10.1192/bjb.2017.11>
- Morrison, E., & MacKinnon, N. J. (2008). Workplace wellness programs in Canada: An exploration of key issues. *Healthcare Management Forum*, 21(1), 26–32. [https://doi.org/10.1016/S0840-4704\(10\)60126-3](https://doi.org/10.1016/S0840-4704(10)60126-3)
- Myhr, A., & Augestad, L. B. (2013). Chronic pain patients—Effects on mental health and pain after a 57-week multidisciplinary rehabilitation program. *Pain Management Nursing: Official Journal of the American Society of Pain Management Nurses*, 14(2), 74–84. <https://doi.org/10.1016/j.pmn.2010.09.005>
- Nemeroff, C. B., Bremner, J. D., Foa, E. B., Mayberg, H. S., North, C. S., & Stein, M. B. (2006). Posttraumatic stress disorder: A state-of-the-science review. *Journal of Psychiatric Research*, 40(1), 1–21. <https://doi.org/10.1016/j.jpsychires.2005.07.005>
- Nielson, E. M., May, D. G., Forcehimes, A. A., & Bogenschutz, M. P. (2018). The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. *Frontiers in Pharmacology*, 9, 132. <https://doi.org/10.3389/fphar.2018.00132>
- O'Reilly, M., Svirydzienka, N., Adams, S., & Dogra, N. (2018). Review of mental health promotion interventions in schools. *Social Psychiatry and Psychiatric Epidemiology*, 53(7), 647–662. <https://doi.org/10.1007/s00127-018-1530-1>
- Osimo, E. F., Pillinger, T., Rodriguez, I. M., Khandaker, G. M., Pariante, C. M., & Howes, O. D. (2020). Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. *Brain, Behavior, and Immunity*, 87, 901–909. <https://doi.org/10.1016/j.bbi.2020.02.010>
- Pratt, M., Stevens, A., Thuku, M., Butler, C., Skidmore, B., Wieland, L. S., Clemons, M.,



- Kanji, S., & Hutton, B. (2019). Benefits and harms of medical cannabis: A scoping review of systematic reviews. *Systematic Reviews*, 8(1), 320. <https://doi.org/10.1186/s13643-019-1243-x>
- Richardson, K. M. (2017). Managing employee stress and wellness in the new millennium. *Journal of Occupational Health Psychology*, 22(3), 423–428. <https://doi.org/10.1037/ocp0000066>
- Rieder, R., Wisniewski, P. J., Alderman, B. L., & Campbell, S. C. (2017). Microbes and mental health: A review. *Brain, Behavior, and Immunity*, 66, 9–17. <https://doi.org/10.1016/j.bbi.2017.01.016>
- Ross, C. K., Frommelt, G., Hazelwood, L., & Chang, R. W. (1987). The role of expectations in patient satisfaction with medical care. *Journal of Health Care Marketing*, 7(4), 16–26.
- Ross, P. T., & Bibler Zaidi, N. L. (2019). Limited by our limitations. *Perspectives on Medical Education*, 8(4), 261–264. <https://doi.org/10.1007/s40037-019-00530-x>
- Rothbaum, B. O., Cahill, S. P., Foa, E. B., Davidson, J. R. T., Compton, J., Connor, K. M., Astin, M. C., & Hahn, C.-G. (2006). Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. *Journal of Traumatic Stress*, 19(5), 625–638. <https://doi.org/10.1002/jts.20170>
- Russell, R. D., Black, L. J., Pham, N. M., & Begley, A. (2020). The effectiveness of emotional wellness programs on mental health outcomes for adults with multiple sclerosis: A systematic review and meta-analysis. *Multiple Sclerosis and Related Disorders*, 44, 102171. <https://doi.org/10.1016/j.msard.2020.102171>
- Schindler, E. A. D., Gottschalk, C. H., Weil, M. J., Shapiro, R. E., Wright, D. A., & Sewell, R. A. (2015). Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. *Journal of Psychoactive Drugs*, 47(5), 372–381. <https://doi.org/10.1080/02791072.2015.1107664>
- Schlag, A. K., O’Sullivan, S. E., Zafar, R. R., & Nutt, D. J. (2021). Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics. *Neuropharmacology*, 191, 108586. <https://doi.org/10.1016/j.neuropharm.2021.108586>



- Slavin, S. J., Schindler, D. L., & Chibnall, J. T. (2014). Medical student mental health 3.0: Improving student wellness through curricular changes. *Academic Medicine: Journal of the Association of American Medical Colleges*, 89(4), 573–577. <https://doi.org/10.1097/ACM.0000000000000166>
- Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence* (p. 11955). (2008). National Academies Press. <https://doi.org/10.17226/11955>
- Tupper, K. W., Wood, E., Yensen, R., & Johnson, M. W. (2015). Psychedelic medicine: A re-emerging therapeutic paradigm. *Canadian Medical Association Journal*, 187(14), 1054–1059. <https://doi.org/10.1503/cmaj.141124>
- Ursano, R. J., Bell, C., Eth, S., Friedman, M., Norwood, A., Pfefferbaum, B., Pynoos, J. D. R. S., Zatzick, D. F., Benedek, D. M., McIntyre, J. S., Charles, S. C., Altshuler, K., Cook, I., Cross, C. D., Mellman, L., Moench, L. A., Norquist, G., Twemlow, S. W., Woods, S., ... Steering Committee on Practice Guidelines. (2004). Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. *The American Journal of Psychiatry*, 161(11 Suppl), 3–31.
- van der Watt, G., Laugharne, J., & Janca, A. (2008). Complementary and alternative medicine in the treatment of anxiety and depression. *Current Opinion in Psychiatry*, 21(1), 37–42. <https://doi.org/10.1097/YCO.0b013e3282f2d814>
- Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression. *Journal of Humanistic Psychology*, 57(5), 520–564. <https://doi.org/10.1177/0022167817709585>
- Weeks, W. B., Leininger, B., Whedon, J. M., Lurie, J. D., Tosteson, T. D., Swenson, R., O’Malley, A. J., & Goertz, C. M. (2016). The Association Between Use of Chiropractic Care and Costs of Care Among Older Medicare Patients With Chronic Low Back Pain and Multiple Comorbidities. *Journal of Manipulative and Physiological Therapeutics*, 39(2), 63-75.e2. <https://doi.org/10.1016/j.jmpt.2016.01.006>
- Weiss, J. B., Vu, M. M., Hatch, Q. M., & Sohn, V. Y. (2021). Maintaining Wellness and Instilling



Resilience in General Surgeons. *Surgical Clinics of North America*, 101(4), 625–634.
<https://doi.org/10.1016/j.suc.2021.05.009>

Whitaker, R. (2005). Anatomy of an Epidemic:
 Psychiatric Drugs and the Astonishing Rise
 of Mental Illness in America. *Ethical Human
 Psychology and Psychiatry*, 7(1), 23–35.

Widiger, T. A., & Samuel, D. B. (2005). Diagnostic
 categories or dimensions? A question for the
 Diagnostic And Statistical Manual Of
 Mental Disorders--fifth edition. *Journal of
 Abnormal Psychology*, 114(4), 494–504.
[https://doi.org/10.1037/0021-843X.114.4.49](https://doi.org/10.1037/0021-843X.114.4.494)

4

Zwahlen, M., Renehan, A., & Egger, M. (2008).
 Meta-analysis in medical research:
 Potentials and limitations. *Urologic
 Oncology*, 26(3), 320–329.
[https://doi.org/10.1016/j.urolonc.2006.12.00](https://doi.org/10.1016/j.urolonc.2006.12.001)

1

Appendix A: participant Comments

Categories	Comments	Subcategories
Category A <i>Mysticism/ spirituality</i>	“Good trips” {Psilocybin}	
	“Life changing, found my soul, peace” {Psilocybin}	B
	“Using these medicines is a very important part of my life spiritually; it is the basis of my shamanistic path in life. I oversee and run ceremonies myself and attribute the ability to keep my depression and anxiety in check to using these medicines. I was a daily Cannabis user for 10+ years, and have now been free from that for 10+ years. I have a very healthy diet, am very compassionate and considerate, do not drink alcohol or smoke, do not take any pills or any other medications, and have a robust immune system. These medicines have been an incredible gift in my life and continue to give me meaning and purpose.” {Psilocybin}	D
	“the use of psychedelics has helped me heal mind body and soul, set and setting are vitally important, as are intentions” {Psilocybin}	
	“Willingness to learn, extremely teachable and have been looking into spiritual retreats for healing purposes” {Psilocybin}	B,C
	“I experienced ego death and am no longer strongly attached to my sense of self. Anxiety comes and goes, and I invite it to tea, give it a hug, and then go on enjoying the miracle that is existing in this body.” {Psilocybin}	D
	“Visualization, mental realization; sense of lightness, joy” {Psilocybin}	E
	“I see colors, I also get the feeling I need to poop but can't. Things will move on the walls. I have had emotional reactions before on mushrooms” {Psilocybin}	E
	“Slight visualizations, music sounded great. I couldn't stop smiling and I felt weightless and worry free.” {Psilocybin}	B
	“Euphoria, relaxation, lessening of pain, dissociation, detachment from surroundings, feelings of floating out of body” {Ketamine}	D,E

-
- “Confused with little sense odd direction. Visual effects going from tracers to being in a different reality all together. Sleep state on a internal kind of trip. Seemed to hav sense of touch in dream..??” {LSD} E
- “Digital closed-eye visuals of remarkable colors and shapes, a gentle shaking or convulsions usually in my legs. Breathing deep and stretching felt incredible. Occassional bolt of a Kundalini-type electric energy that starts in the lowest chakra and rockets up the spine, culminating in a vibratory, almost audible noise...think a comination of a joy-buzzer and an orgasm located right where the pineal would be. Certainly moments of emotional catharsis yet I am unable to dial in what the tears were about. General sense of oneness with everything. A switch went off where I started addressing everything, inanimate or not as a "thou" instead of an "it"” {Psilocybin}
- “Geometrical visions, peacefulness, calmness, turns my over anxious brain off” {Ayahuasca} D
- “positive mood, spiritual connection, positive visions I connect to spirit world, feeling of wanting to improve physical well-being” {Psilocybin} B
- “Purging, shaking, emotional/mental awakening, spiritual experiences, visual affects, positive affects on life” {Psilocybin} B,E
- “Very visual, very connected, feelings of deep love and understanding of the universe. Visuals were mainly geometric patterns. With eyes open felt almost normal except certain things, mainly electronics, looked liked old 3-D movies without the glasses. I have also experienced ayahuasca being led by a shaman. Magical experience. The music played was alive. I could hear the violin breathing. Beautiful experience. Visuals started as geometric patterns, changed to an entire experience following the shaman who had picked the vines to make the ayahuasca. Too much to detail here about the experience. I went in with no intention except to experience. Psilocybin has had a much greater impact on my mental health.” {Psilocybin} B,D
- “shaking; nausea; yawning; visual effects (intensely detailed, exquisite and ethereal patterns and visions; connection with and guidance from holy spirit; revelatory messages of life's purpose and meaning; unforgettable experiences of infinite, eternal, divine love” {Ayahuasca} E
- “all of the above and more, healing and morphing into animals ,seeing aliens and angels being in the spirit realm” {Ayahuasca}
-

Gupta et al.



-
- “My most recent and continued experiences are used by myself as a bit of a reset to get me back to the place balance and understanding that I got myself to through my experiences and journeys in looking into myself through guided Ayahuasca ceremonies.” {Psilocybin}
- “Ayahuasca profoundly effected my wellness. It allowed me to let go of emotional loads I'd been carrying and make significant positive changes to my activities (e.g., adding value-based activities, reduced patterns of work-a-holism, improved self-care) and to my relationships.” {Ayahuasca} C
- “These ceremonies uncovered a deep lack of self-love and the source of this lack. I continue to try to cultivate and build on this compassion for myself and others in ongoing therapeutic work.” {Ayahuasca} C
- “The most important event to ever happen to me that was the beginning of a healing journey” {Psilocybin}
- “I don't feel like situations bother me as much as they would have prior to, if an emotion is elevated I handle it much better, move on and am not ruminating the rest of the day or week.” {Ketamine} C,D
- “Unity experiences, increased awareness and senses, decreased mental restlessness and impulsiveness, decreased negative self-talk.” {Marijuana} A
- “Access to parts of my self/brain/introspection that I cannot sober (visuals and being able to recognise and interact with more than my internal monologue), a sense of wholeness/being complete/not lacking, a sense of the perfection of experiences (especially ones associated with my CPTSD, and appreciating the influence they had on me and how I can keep growing)” {Psilocybin} A
- “mental realization and spiritual awakening and clarity” {Psilocybin}
- “It was brilliant, a truly remarkable experience that brought about a desire to seek therapy to understand what happened to me, to learn new ways of navigating in my life. I want to be able to experience it again but with a therapist present.” {Psilocybin}
- “Love, peace. Acceptance” {Psilocybin}
- “Where to start? Serenity, courage, wisdom, presence, happiness proceeding circumstances, gratitude.” {Psilocybin}
- “I've been feeling overall lighter since the experience.” {Ecstasy} A,C
-

“Prior to my work with these medicines, I experienced many of the above symptoms and would mask with using alcohol or cannabis. I have not used either substance for over a year now. I should also mention that the question about how many time I’ve used these medicines didn’t have a time qualifier. I answered based on my ‘lifetime use’ of these medicines, which is about 3 years. I found these medicines to be more effective than the counseling that I have received in my life, tho a combination would be very effective, I imagine. These medicines have helped me to connect to my spirit and all of nature! Have helped me to recover suppressed memories, and to let go and forgive others and myself. I do not fear death and exist in a grateful state.” {Psilocybin}

“My wish and dream is for plant medicine to be legalized and made available globally to people who need and want it for healing purposes, administered in safe, supervised settings, with integration support. Words really fail, but for me, the gifts of ayahuasca have been profoundly, permanently and positively life-changing on all levels: physical, emotional, social, psychological, cosmic and spiritual (this is despite having had some harrowing experiences in not very safe foreign settings.) Thank you.” {Ayahuasca} A,D,E

“the use of chants ,meditation, and psychedelics together has greatly improved my life” {Ayahuasca} A

“I have a clearer understanding of where my mental health and any physical pain play a role in my life; I have a better acceptance of things in my life and am not held back by these things.” {Psilocybin} D

“These medicines should be available to healthy people as well as those with anxiety, depression, or chronic pain. They can help people expand their understandings of reality and existence. They certainly did that for me. My problems are so minute now that I feel as though I can weather any storm. Even being imprisoned, tortured, etc. Breathe through it, know that pain, suffering, and even death is impermanent. It's ok to fear these things, but don't run away from them. Befriend them and know that they too will pass. Or at least, these things FEEL like the truth now. Life is beautiful AND hideous. As it should be.” {Psilocybin} D,E

“Getting to a state of acceptance, Release of subconscious, pent up emotions, Realizations of things I am either avoiding or missing in my routines that are negatively affecting my moods and interactions with others” {Psilocybin} C

Category C <i>Social connection and Cultural impact</i>	“My psilocybin ceremony changed my life in an amazing way. I am a better mother and better person because of my experience” {Psilocybin}	A
	“Socialness, clarity, visual hallucinations, increased sensations body buzz” {Ecstasy}	E
	“purging, shaking, crying, spiritual experiences (feeling of being loved, feeling of connection to humanity), intense emotional processing (processing of past attachment injuries, meaning making, self-compassion, moving through unfinished business in interpersonal relationships [parents, past romantic attachments])” {Ayahuasca}	A,E
	“Purging, shaking, emotional catharsis, revisiting traumatic memories, experience of unconditional love for self and others, forgiveness of self and others, visions of fractals, snakes, & jaguar.” {Ayahuasca}	A,E
Category D <i>Impact on medical/ mental health condition</i>	“Beneficence, interconnectedness, some eye "wiggling action" but not necessarily present, intrapersonal and interpersonal intimacy” {Psilocybin}	
	“Overall stress and anxiety when down for short period after but always comes back.” {LSD}	E
	“I have never had a guided session before and have always followed advice from professionals. Micro dosing helps release the daily pain and brain fog but I need a stronger dose monthly to remove the brain fog.” {Psilocybin}	
	“Microdosing on days I don’t take my Anxiety meds def help keep me grounded. It brings a calmness that my anxiety meds don’t give me.” {Psilocybin}	B
	“It helps for a bit but it's not a life time change just like any medication” {Psilocybin}	E
	“The side effects of the pain in my back and chest continued for several days after the ceremonies and felt like something in my body was healing, as I then had less of the usual chronic pain I normally deal with for several months following these experiences.” {Ayahuasca}	A,E
	“Decrease in use of alcohol/cannabis, less pain, improved boundaries, sense of peace/joy, resolution of past trauma” {Psilocybin}	C
	“I have suffered from undiagnosed social anxiety all my life. Mushrooms have changed my life. I no longer have that anxiety, fully engage in conversation and social settings, more comfortable in my own skin. It has	C

-
- been and amazing transformation. Will never go back to pharmaceuticals Way more effective and no side effects.” {Ayahuasca}
- “I wasn't expected to love past winter two years ago. With combination of microdosing meth alongside prescribed meds and physically moving back to nature I fell I will be alive next spring and possibly longer” {Methamphetamine} B
- “Working with Ayahuasca over the past 6-7 years has been both the most challenging and transformative experience of my life. It has utterly and completely changed my belief system, life perspective, mood, and sense of purpose, all for the positive. It has cured - yes, cured - a variety of addictions, including chronic alcoholism. After a lifetime of depression and anxiety, this medicine has taken me to a place of deep gratitude, joy and inner peace. My atheistic, nihilistic outlook has been replaced with a divine spiritual connection that is with me always.” {Ayahuasca} A
- “Experience of oneness, visual, takes away my tooth pain and body pain” {Psilocybin} A
- “Muscle spasms ease , pain is better” {LSD}
- “Mental resolution, removed brain fog, relieved pain in my joints and head, relieved anxiety for up to about a month” {Psilocybin} E
- “Prior to my ayahuasca experience, I had suffered from and eating disorder (anorexia). I'd been in recovery for ~10years prior to the medicine, but still had a lot of work to do on processing the emotions that contributed to my original development of mental health problems. Aya helped me process and move through in ways that my experiences in traditional therapy had not.” {Ayahuasca}
- “My anxiety and depression are a result of my ASD and chronic pain (PTSD less so because my triggers are far between or related to the ASD and pain) that I've accumulated while being told I was “normal” and there was nothing wrong with me. The substances I have tried have made existing in my brain so much easier, have helped me understand myself and take the time to slow down or decline activities that would severely impact my mobility for days (before if I declined the mental health impacts were more severe and harder to live with than the pain.” {Psilocybin} B
-

-
- “Im still on a 1/2 dose of anti depressants (before Ibagaine i was on 20 mg of prozac per day for 30 years) i E
 tried to stop 1 1/2 years ago but went into a severe depressive state. After Ibagaine i get in 1/2. I plan od
 doing it again and going totally off meds! I feel good now. Had severe PTSD prior” {Ibogaine}
- “I would like to help in any way I can with this research and any other projects regarding Veteran's Mental B
 Health. I feel very much like my old self since finishing K treatment and would/will encourage others to
 pursue it.” {Ketamine}
- “By far the best thing I have ever done...sadly Mental health care has a waiting list...I can't get in to see E
 anyone for months for my CPTSD, real mental health care is only for the rich. So I began taking matters into
 my own hands. Microdosing and also the one big 4gram trip. Now I'm ready to heal...but can't get in to do
 it.” {Psilocybin}
- “I have come such a long way from the extremely depressed anxious person I was a couple years ago. There
 is still turns to be done but I feel like my experience with psilocybin has definitely changed my life for the
 better. 10/10” {Psilocybin}
- “Psychedelics have a great deal of potential when utilized with a mindful approach. There is no doubt in my
 mind that if I didn't work up the nerve to go through the healing experiences the way I did, I would've
 undoubtedly relapsed and ended up worse off than when I started. Addictions are pain killing substitutes for
 legitimate suffering. Period. Denying ones suffering is denying their true self ti emerge.” {Psilocybin}
- “Euphoria , calm , giggly.” {Psilocybin} A
- “there was a sense of joy and inner peace no visuals nothing spiritual” {Psilocybin}
- “When I can medicate my anger is non existent. I feel happiness that I cannot otherwise obtain. I'm a better
 husband. I am a better father when I can medicate .My wife has noticed a huge difference when I can
 microdose and can not. I find the benefits of microdosing do not last nearly as long as a larger dose. If you
 were to take a macro dose, I find the effects last much longer than microdosing but microdosing seems to
 just maintain it” {Psilocybin}
- “It actually had me figure out my ASD diagnosis, so many distresses and experiences from childhood came C
 to my memory, they ways I had been gaslit into being normal and separating out what pieces were cultural
-

	teachings from my upbringing that just come across as ASD because of an indigenous world view” {Psilocybin} “In the immediate aftermath of drinking Ayahuasca, all of my symptoms were alleviated. Time away from the medicine and circumstances led to some setbacks” {Ayahuasca} “Please note my answers to the pain, mental health, etc etc are based on how I feel now on the mushrooms. My answers would have been very different if you had asked how I felt before the microdosing and therapeutic trips.” {Psilocybin}	E
Category E <i>Neutral</i> <i>impression,</i> <i>sensations or</i> <i>difficult</i> <i>experiences</i>	“No side effects for micro-dosing. For Marijuana the biggest drawback is how often you have to self-treat and the fact that it lasts little beyond experience and so the tendency is to use more often and at that time that comes with the disadvantages (not being able to drive, work, etc.).” {Marijuana} “dizzy, drowsy, tired” (translated from french) {Methamphetamine} “Still integrating the experience” {Ecstasy} “I have not used these for anything” {None} “Hallucinated and had a bit of shaking” {Ketamine} “auditory hallucination, giving morality on the spot, makes you thirsty” (translated from french) {Methamphetamine} “the only associated symptom that I got after a "Trip" was fatigue, some expected anxiety prior too” {Ketamine} “Physical heaviness/weight” {Psilocybin} “Some things can't be medicated. Taking something regularly isn't helping a problem.” {LSD} “I'm at the end of it, I realize it” (translated from french) {Methamphetamine} “Most of my anxiety and depression are specific to the anticipatory grief over the impending loss of my best friend, my dog Plucky” {Psilocybin} “F**k you” {Psilocybin} “Get f**ked” {Psilocybin}	



“None of your f**king business parasites.” {Psilocybin}

“Need more info on this” {Marijuana}

“Thank you for such an interesting study opportunity. I look forward to hearing from you.” {Ketamine}